Marc Goodman
Stock Analyst at Leerink Partners
(2.91)
# 1,634
Out of 4,910 analysts
96
Total ratings
55.56%
Success rate
27.23%
Average return
Main Sectors:
Stocks Rated by Marc Goodman
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| AMLX Amylyx Pharmaceuticals | Upgrades: Outperform | $4 → $10 | $8.30 | +20.48% | 5 | May 7, 2025 | |
| OPT Opthea | Downgrades: Market Perform | $12 → $1 | $3.41 | -70.67% | 2 | Mar 25, 2025 | |
| AXSM Axsome Therapeutics | Maintains: Outperform | $110 → $150 | $104.97 | +42.90% | 7 | Feb 10, 2025 | |
| RLMD Relmada Therapeutics | Downgrades: Market Perform | $10 → $1 | $0.67 | +50.33% | 3 | Dec 4, 2024 | |
| BHVN Biohaven | Maintains: Outperform | $55 → $60 | $13.69 | +338.28% | 6 | Sep 23, 2024 | |
| LENZ LENZ Therapeutics | Initiates: Outperform | $32 | $33.46 | -4.35% | 1 | Apr 15, 2024 | |
| BLTE Belite Bio | Initiates: Outperform | $25 | $62.42 | -59.95% | 1 | Jul 26, 2023 | |
| DNLI Denali Therapeutics | Initiates: Outperform | $50 | $14.31 | +249.41% | 1 | Jan 30, 2023 | |
| EOLS Evolus | Maintains: Outperform | $18 → $20 | $9.64 | +107.58% | 3 | Jan 19, 2023 | |
| NBIX Neurocrine Biosciences | Maintains: Market Perform | $100 → $115 | $131.64 | -12.64% | 4 | Nov 2, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $270 → $310 | $132.59 | +133.80% | 11 | Oct 26, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $6 → $12 | $11.25 | +6.67% | 2 | Aug 11, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $40 → $46 | $31.00 | +48.39% | 4 | Aug 11, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $27 → $21 | $23.06 | -8.91% | 5 | Aug 9, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $200 → $210 | $118.01 | +77.95% | 5 | Aug 4, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Market Perform | $50 → $40 | $8.76 | +356.62% | 5 | Jul 11, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $15 → $10 | $2.43 | +311.52% | 2 | Jul 11, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Market Perform | $24 → $27 | $26.53 | +1.77% | 5 | Apr 28, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $24 → $15 | $5.44 | +175.74% | 2 | Dec 21, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $300 → $270 | $513.55 | -47.42% | 5 | Mar 13, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $79 → $96 | $190.83 | -49.69% | 5 | Nov 19, 2019 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | n/a | $48.94 | - | 2 | May 21, 2018 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $72 → $67 | $84.11 | -20.34% | 3 | Oct 30, 2017 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $84 → $98 | $28.11 | +248.63% | 7 | Oct 5, 2017 |
Amylyx Pharmaceuticals
May 7, 2025
Upgrades: Outperform
Price Target: $4 → $10
Current: $8.30
Upside: +20.48%
Opthea
Mar 25, 2025
Downgrades: Market Perform
Price Target: $12 → $1
Current: $3.41
Upside: -70.67%
Axsome Therapeutics
Feb 10, 2025
Maintains: Outperform
Price Target: $110 → $150
Current: $104.97
Upside: +42.90%
Relmada Therapeutics
Dec 4, 2024
Downgrades: Market Perform
Price Target: $10 → $1
Current: $0.67
Upside: +50.33%
Biohaven
Sep 23, 2024
Maintains: Outperform
Price Target: $55 → $60
Current: $13.69
Upside: +338.28%
LENZ Therapeutics
Apr 15, 2024
Initiates: Outperform
Price Target: $32
Current: $33.46
Upside: -4.35%
Belite Bio
Jul 26, 2023
Initiates: Outperform
Price Target: $25
Current: $62.42
Upside: -59.95%
Denali Therapeutics
Jan 30, 2023
Initiates: Outperform
Price Target: $50
Current: $14.31
Upside: +249.41%
Evolus
Jan 19, 2023
Maintains: Outperform
Price Target: $18 → $20
Current: $9.64
Upside: +107.58%
Neurocrine Biosciences
Nov 2, 2022
Maintains: Market Perform
Price Target: $100 → $115
Current: $131.64
Upside: -12.64%
Oct 26, 2022
Maintains: Outperform
Price Target: $270 → $310
Current: $132.59
Upside: +133.80%
Aug 11, 2022
Maintains: Outperform
Price Target: $6 → $12
Current: $11.25
Upside: +6.67%
Aug 11, 2022
Maintains: Outperform
Price Target: $40 → $46
Current: $31.00
Upside: +48.39%
Aug 9, 2022
Maintains: Outperform
Price Target: $27 → $21
Current: $23.06
Upside: -8.91%
Aug 4, 2022
Maintains: Outperform
Price Target: $200 → $210
Current: $118.01
Upside: +77.95%
Jul 11, 2022
Maintains: Market Perform
Price Target: $50 → $40
Current: $8.76
Upside: +356.62%
Jul 11, 2022
Maintains: Outperform
Price Target: $15 → $10
Current: $2.43
Upside: +311.52%
Apr 28, 2022
Maintains: Market Perform
Price Target: $24 → $27
Current: $26.53
Upside: +1.77%
Dec 21, 2021
Maintains: Outperform
Price Target: $24 → $15
Current: $5.44
Upside: +175.74%
Mar 13, 2020
Maintains: Buy
Price Target: $300 → $270
Current: $513.55
Upside: -47.42%
Nov 19, 2019
Maintains: Buy
Price Target: $79 → $96
Current: $190.83
Upside: -49.69%
May 21, 2018
Downgrades: Neutral
Price Target: n/a
Current: $48.94
Upside: -
Oct 30, 2017
Maintains: Buy
Price Target: $72 → $67
Current: $84.11
Upside: -20.34%
Oct 5, 2017
Maintains: Buy
Price Target: $84 → $98
Current: $28.11
Upside: +248.63%